Hôpital Henri-Mondor, Département de gastroentérologie, 51, boulevard du Maréchal de Lattre de Tassigny, 94010 Créteil
Université Paris Est Créteil, Équipe universitaire EA7375-EC2M3, Créteil
Cancer immunotherapy use and more specifically checkpoint inhibitor is currently rising based on dramatic improvement of prognosis of many cancers such as metastatic melanoma and some subtypes of lung cancer. Checkpoint inhibitors are now implemented in many other cancers including those of the gastrointestinal tract. The contribution of intestinal microbiome has been suggested through many studies allowing some microbial fingerprints to predict efficacy and safety. Indeed, some patients may experience immune-related adverse events notably enterocolitis mimicking inflammatory bowel disease. This paper describes the specific contribution of intestinal microbiome to efficacy and safety of checkpoint inhibitors.